This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Stock Mailbag: ASCO, Sarepta, Cel-Sci and Hate Mail!

Stocks in this article: SRPT AMRN AVEO SNTA CVM

BOSTON ( TheStreet) -- I'm trying to incorporate more actual tweets in the Biotech Stock Mailbag.

Earlier this week, the American Society of Clinical Oncology (ASCO) posted the itinerary planner for its annual meeting. Research abstract titles and presentation times are now available and searchable.

I fear this year's ASCO meeting might be a tad boring from a Wall Street perspective. ASCO is cyclical, with strong and weak years. The upcoming meeting looks to be the latter. With that said, here are some highlights based on my first, quick look through the abstracts:

This year's plenary session features two presentations on Roche's (RHHBY) Avastin, one each in glioblastoma (brain cancer) and cervical cancer. Onyx Pharmaceuticals (ONXX) will also present results from the phase III "Decision" trial of Nexavar in thyroid cancer.

Synta Pharmaceuticals (SNTA): Updated results from the phase II "Galaxy-1" study of ganetespib in non-small cell lung cancer. Abstract No. CRA8007.

Amgen (AMGN): Detailed results from the positive phase III study of T-Vec in melanoma. Abstract No. LBA9008.

Ariad Pharmaceuticals (ARIA): Updated results from the early, proof-of-concept study of AP26113. Abstract No. 8031

Gilead Sciences (GILD) will have several presentation on PI3k inhibitor idealisib. Check out abstract nos. 8519, 7005, 8500 and 8501.

Bristol-Myers Squibb's (BMY) anti PD-1 nivolumab will definitely take a star turn at the ASCO meeting this year. Check out abstract nos. 9011, 9012, CRA9006 and 3002.

Roche also has a PD-L1 antibody, MPDL3280A, in development. Abstract Nos. 4505, 3000 and 8008.

FDA just awarded Merck's (MRK) anti PD-1 lambrolizumab with breakthrough therapy designation. Check out abstract no. 9009.

Oncothyreon (ONTY): The failed Stimuvax lung cancer phase III trial will be presented. Abstract No. 7500.

Array Biopharma (ARRY): Phase II data from the combination study of selumitinib plus dacarbazine in melanoma. Abstract No. 9004

That's a start. The contents of most of the ASCO research abstracts will be posted online May 15 at 6 pm ET. There will be much more to talk about once we get more than just the titles.

Sarepta Therapeutics (SRPT) shares are weak due to heightened speculation that FDA will reject the company's request to seek accelerated approval for its Duchenne muscular dystrophy drug eteplirsen. The confidence of the "no accelerated approval" crowd has been bolstered by a series of conference calls sponsored by sell-side analysts over the past week. These calls have featured experts expressing doubts about Sarepta's ability to correlate dystrophin production with the benefit observed by patients on the six-minute walk test.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs